Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.
about
Akt-and CREB-mediated prostate cancer cell proliferation inhibition by Nexrutine, a Phellodendron amurense extractA systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortalityAnticancer activity of extracts derived from the mature roots of Scutellaria baicalensis on human malignant brain tumor cellsDeveloping a library of authenticated Traditional Chinese Medicinal (TCM) plants for systematic biological evaluation--rationale, methods and preliminary results from a Sino-American collaboration.Herbs in hemato-oncological care: an evidence-based review of data on efficacy, safety, and drug interactions.Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapySaudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.Targeting angiogenesis with integrative cancer therapies.Molecular mechanisms of denbinobin-induced anti-tumorigenesis effect in colon cancer cells.Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis.Soy isoflavones exert differential effects on androgen responsive genes in LNCaP human prostate cancer cells.Management of androgen-independent prostate cancer.Complementary and alternative medicines in prostate cancer: from bench to bedside?A Systematic Review of Randomized Controlled Trials on Oral Chinese Herbal Medicine for Prostate Cancer.Clinical outcomes of helical tomotherapy for super-elderly patients with localized and locally advanced prostate cancer: comparison with patients under 80 years of ageGynecomastia in patients with prostate cancer: update on treatment options.Chinese medicine and biomodulation in cancer patients--Part one.Anticancer effects of Chinese herbal medicine, science or myth?The role of quality assurance and standardization in the safety of botanical dietary supplementsPerspectives on treatment of metastatic castration-resistant prostate cancer.Low-dose diethylstilbestrol for the treatment of advanced prostate cancerCastration-resistant metastatic prostate cancer: current status and treatment possibilities.New developments in castrate-resistant prostate cancer.Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?Wedelia chinensis inhibits nasopharyngeal carcinoma CNE-1 cell growth by inducing G2/M arrest in a Chk1-dependent pathway.Combined activity of oridonin and wogonin in advanced-stage ovarian cancer cells: sensitivity of ovarian cancer cells to phyto-active chemicals.Down-regulation of androgen-receptor and PSA by phytochemicals.Treatment algorithm in hormone-resistant prostate cancer: Practical guidelines.Gynaecomastia linked to the intake of a herbal supplement fortified with diethylstilbestrol.Evaluation of How Integrative Oncology Services Are Valued between Hematology/Oncology Patients and Hematologists/Oncologists at a Tertiary Care Center.
P2860
Q24676177-657DA729-F446-4EF6-AFD6-C185003030ACQ26782066-D7F74358-B93D-4229-955F-0C16AAF0ED1FQ28767955-A7F3B2E3-F359-4E8F-9269-5896D8D51515Q30498042-8E9B1670-265E-4172-ABE7-114D740BA1D4Q33596382-3741AA00-5978-400B-8388-3F35D80C44B0Q33775549-B00A10F2-FBC0-4574-8B91-5073A3C27005Q34437308-CE16D081-A680-4C65-A763-9956BC448F66Q34495463-0223104E-5B5D-4D35-85AE-B1E3B196500DQ35010953-D834384B-41C8-448F-97DB-F01698C9E1E7Q35942893-673AA727-9C2C-45AB-A83E-5802BEC59DF9Q35989052-485EDC98-3EE9-4A26-93C4-1D7AB449F6A4Q35996488-456F895A-31A7-478A-BB97-E50CAF50BAD6Q36051522-5418D91B-7223-4EF7-9496-7D513FA6A3DEQ36094649-5E5BB729-057F-4A18-AC4D-C4F48EAC2009Q36234731-4DF54BA1-3B25-4A5D-803B-4E13C0D352EEQ36375981-B17DEAE9-90A3-421E-874D-D1A07D41DD1BQ36485229-B2913C65-1014-4388-9680-3E33A6BCAE14Q36656096-7935E340-C7EB-480A-8CBC-00327159CAAEQ36760276-57A3AD43-0161-4455-BF4D-DD90FC0EDBB6Q36871685-D8F5C064-9ACE-4172-9913-FDFDAA797454Q37906889-D5E18940-3266-4261-BB36-288D3038FA97Q37989075-1DD334C4-18E6-43B5-8770-EB160BA853DAQ38016532-AE7FA95A-882A-4DD2-A916-A923D831D595Q38195921-F7911DAB-52C1-4128-826C-B0AF753F7905Q39081093-D2196222-623F-4C35-9A61-70DBD26C164CQ39651374-E7426562-9B3E-47B7-B38D-2A0230960A27Q40023730-55B02BCD-6837-4D8B-A895-C30DC88DAB1AQ43077983-DB500D35-C109-4C23-B4B7-AF38D8886647Q43078841-4520CCEE-A704-4165-8B50-955475562657Q55334671-26572B1C-1C39-4CF3-AC81-12AA9EB4BE78
P2860
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Prospective, multicenter, rand ...... n-independent prostate cancer.
@ast
Prospective, multicenter, rand ...... n-independent prostate cancer.
@en
Prospective, multicenter, rand ...... n-independent prostate cancer.
@nl
type
label
Prospective, multicenter, rand ...... n-independent prostate cancer.
@ast
Prospective, multicenter, rand ...... n-independent prostate cancer.
@en
Prospective, multicenter, rand ...... n-independent prostate cancer.
@nl
prefLabel
Prospective, multicenter, rand ...... n-independent prostate cancer.
@ast
Prospective, multicenter, rand ...... n-independent prostate cancer.
@en
Prospective, multicenter, rand ...... n-independent prostate cancer.
@nl
P2093
P921
P356
P1476
Prospective, multicenter, rand ...... en-independent prostate cancer
@en
P2093
Brian I Rini
Eric J Small
Glenn J Bubley
Graham Jones
Matthew R Smith
Mika K Derynck
Robert Bok
Robert S DiPaola
Robert T Rosen
Vivian Weinberg
P304
P356
10.1200/JCO.2004.10.195
P407
P577
2004-08-02T00:00:00Z